Antivirals TRIZ Cases

Modified RNA interference agents silence hepatitis B virus transcripts to achieve sustained virologic response without triggering drug resistance.

Improved asunaprevir synthesis enables potent antiviral regimens that reduce treatment duration and adverse effects associated with pegIFNα/RBV.

A Formula I nucleoside analog inhibits viral RNA-dependent RNA polymerase to treat Coronaviridae infections.

Merging amantadine, ribavirin, and oseltamivir enhances viral sensitivity while preventing drug-resistant strain emergence.

A peptide-conjugated protoporphyrin IX compound crosses the blood-brain and blood-placental barriers to target viral infections.

Supercritical oleander extract delivers antiviral activity against Ebola and Marburg viruses.

Detecting anti-ACE2 IgM antibodies diagnoses severe COVID-19 risk, enabling early treatment to prevent organ damage.

Screened FDA-approved compounds inhibit SARS-CoV-2 infection using Vero cell assays.

Engineering TCR-deficient T cells with chimeric receptors eliminates cancer targets while preventing graft-versus-host disease and relapse.

Segmented precursors stabilize hypochlorous acid, resolving toxicity and instability issues in conventional chlorine oxide disinfectants.

Third-party specific T cells eliminate GVH reactive populations via IL-15 culture, resolving the trade-off between preventing graft rejection and avoiding GVHD.

Compounds bind to the dengue virus E protein groove to block host cell entry and virion assembly, addressing the lack of specific antiviral therapies.

Antisense oligodeoxynucleotides target JC virus replication sequences to inhibit viral multiplication.

C-28 modified betulinic acid compounds resolve bioavailability trade-offs while blocking CA-SP1 cleavage for effective HIV-1 maturation inhibition.

A composite traditional Chinese medicine formulation inhibits viral replication through synergistic multi-target action.

AT2R agonist lowers E-cadherin levels to inhibit viral entry, resolving the contradiction between hypertension treatment and infection risk.

Targeting PI3K/mTOR pathways restores metabolic flux and reduces viral titers despite antigenic drift.

Combining Marrubium, Ribes nigrum, and Borago officinalis extracts creates an antiviral composition.

A reverse transcription PCR method uses primers targeting conserved 3' untranslated regions to detect avian nephritis virus.

Mixture of inactivated influenza A viruses with distinct hemagglutinin subtypes elicits heterosubtypic immune responses.

Gapmer antisense oligonucleotides degrade SARS-CoV-2 RNA via RNase H recruitment, resolving steric blocking limitations of morpholino therapies.

Heteroaryl sulfone linkers resist plasma protein interference and glutathione decomposition to maintain therapeutic efficacy in ADCs.

Acid extraction and bio-fermentation yield a composition that boosts innate immune response while avoiding hazardous solvents.

Combining artemisone with antiviral compounds achieves synergistic activity against cytomegalovirus while reducing toxicity and drug resistance.

Plant extract antiviral composition inhibits adenovirus and enterovirus attachment, resolving drug resistance trade-offs.